Several studies described associations between high EpCAM/TROP2 expression and poor bladder cancer prognosis (17–20) while others found a relationship with favorable tumor features in adenocarcinoma of non-small cell lung carcinoma (21) and upper tract urothelial carcinoma (22). Here, TACSTD2 is linked to neoplasm.